Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Publishing timestamp: 2024-04-09 06:45:01
Summary
Pfizer's vaccine shows potential to protect adults ages 18 to 59 from RSV, plans to submit data for expanded approval. Pfizer aims to gain more share of RSV market after lagging behind GSK. Initial data suggests Pfizer's shot could help protect a wider population from RSV. Munjal, Pfizer's executive director, highlights the importance of vaccination for high-risk adults. Pfizer's vaccine met phase three trial goals for efficacy and safety in high-risk adults ages 50 to 59.
Sentiment: POSITIVE
Keywords: business news, respiratory syncytial virus, breaking news, health care industry, gsk plc, biotechnology, science, biotech and pharmaceuticals, business, pharmaceuticals, pfizer inc,
Source: https://www.cnbc.com/2024/04/09/pfizer-rsv-vaccine-may-protect-high-risk-adults-ages-18-59.html